| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Defects, Congenital | 33 | 2025 | 72 | 6.590 |
Why?
|
| Cardiac Surgical Procedures | 29 | 2025 | 54 | 5.730 |
Why?
|
| Cardiopulmonary Bypass | 17 | 2020 | 23 | 3.610 |
Why?
|
| Hyperglycemia | 5 | 2019 | 60 | 2.190 |
Why?
|
| Intensive Care Units, Pediatric | 10 | 2018 | 15 | 2.120 |
Why?
|
| Postoperative Complications | 15 | 2025 | 253 | 1.990 |
Why?
|
| Heart Ventricles | 12 | 2024 | 123 | 1.920 |
Why?
|
| Infant | 42 | 2025 | 1143 | 1.710 |
Why?
|
| Length of Stay | 10 | 2023 | 231 | 1.690 |
Why?
|
| Infant, Newborn | 36 | 2025 | 960 | 1.390 |
Why?
|
| Child | 34 | 2025 | 3381 | 1.360 |
Why?
|
| Inflammation | 5 | 2020 | 729 | 1.280 |
Why?
|
| Enteral Nutrition | 2 | 2020 | 17 | 1.230 |
Why?
|
| Fontan Procedure | 5 | 2023 | 11 | 1.220 |
Why?
|
| Nutritional Support | 2 | 2019 | 3 | 1.120 |
Why?
|
| Respiration, Artificial | 6 | 2020 | 47 | 1.110 |
Why?
|
| Hypoplastic Left Heart Syndrome | 9 | 2023 | 10 | 1.060 |
Why?
|
| Critical Care | 7 | 2023 | 48 | 1.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2019 | 10 | 1.020 |
Why?
|
| Heart Diseases | 4 | 2017 | 110 | 0.970 |
Why?
|
| Humans | 87 | 2025 | 42163 | 0.970 |
Why?
|
| Intensive Care, Neonatal | 2 | 2018 | 12 | 0.970 |
Why?
|
| Insulin Resistance | 2 | 2019 | 199 | 0.920 |
Why?
|
| Pulmonary Atresia | 1 | 2024 | 1 | 0.900 |
Why?
|
| Intensive Care Units | 6 | 2023 | 71 | 0.810 |
Why?
|
| Critical Illness | 6 | 2025 | 46 | 0.770 |
Why?
|
| Cardiac Output | 5 | 2016 | 24 | 0.740 |
Why?
|
| Child, Preschool | 18 | 2025 | 1516 | 0.710 |
Why?
|
| Monitoring, Physiologic | 3 | 2016 | 37 | 0.700 |
Why?
|
| Postoperative Care | 6 | 2017 | 19 | 0.690 |
Why?
|
| Fluid Therapy | 2 | 2018 | 29 | 0.690 |
Why?
|
| Hospital Mortality | 7 | 2025 | 206 | 0.680 |
Why?
|
| Retrospective Studies | 21 | 2025 | 2485 | 0.670 |
Why?
|
| Treatment Outcome | 20 | 2023 | 1586 | 0.630 |
Why?
|
| Registries | 6 | 2025 | 431 | 0.620 |
Why?
|
| Calorimetry, Indirect | 2 | 2016 | 9 | 0.590 |
Why?
|
| Insulin | 3 | 2020 | 255 | 0.590 |
Why?
|
| Blood Glucose | 3 | 2016 | 386 | 0.580 |
Why?
|
| Vascular Resistance | 5 | 2016 | 37 | 0.570 |
Why?
|
| Female | 46 | 2025 | 24018 | 0.570 |
Why?
|
| Nutritional Requirements | 1 | 2018 | 33 | 0.570 |
Why?
|
| Magnesium | 1 | 2018 | 93 | 0.550 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 56 | 0.530 |
Why?
|
| Physician-Patient Relations | 2 | 2010 | 146 | 0.520 |
Why?
|
| Ketones | 1 | 2016 | 18 | 0.510 |
Why?
|
| Male | 41 | 2025 | 22779 | 0.510 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 191 | 0.490 |
Why?
|
| Health Promotion | 2 | 2013 | 691 | 0.490 |
Why?
|
| Health Expenditures | 2 | 2018 | 44 | 0.460 |
Why?
|
| Time Factors | 12 | 2025 | 1848 | 0.460 |
Why?
|
| Disease Management | 2 | 2018 | 68 | 0.460 |
Why?
|
| Disasters | 1 | 2016 | 74 | 0.450 |
Why?
|
| Echocardiography | 5 | 2024 | 167 | 0.450 |
Why?
|
| Hemoglobin A | 1 | 2014 | 4 | 0.440 |
Why?
|
| Hemolysis | 1 | 2014 | 59 | 0.430 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 15 | 0.430 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2014 | 15 | 0.430 |
Why?
|
| Glucocorticoids | 5 | 2011 | 92 | 0.430 |
Why?
|
| Health Care Costs | 2 | 2015 | 89 | 0.420 |
Why?
|
| Energy Metabolism | 1 | 2015 | 181 | 0.420 |
Why?
|
| Cost Savings | 1 | 2013 | 18 | 0.420 |
Why?
|
| Assisted Circulation | 1 | 2013 | 4 | 0.410 |
Why?
|
| Mental Disorders | 1 | 2018 | 377 | 0.410 |
Why?
|
| Primary Prevention | 1 | 2013 | 63 | 0.400 |
Why?
|
| Risk Factors | 15 | 2025 | 3942 | 0.400 |
Why?
|
| Fractures, Bone | 2 | 2018 | 61 | 0.400 |
Why?
|
| Hypoglycemia | 1 | 2013 | 24 | 0.400 |
Why?
|
| Erythrocyte Transfusion | 3 | 2018 | 19 | 0.380 |
Why?
|
| Adolescent | 15 | 2025 | 5950 | 0.380 |
Why?
|
| Oxygen | 3 | 2025 | 217 | 0.360 |
Why?
|
| Nutritional Status | 3 | 2018 | 115 | 0.360 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 181 | 0.340 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2010 | 6 | 0.340 |
Why?
|
| Prospective Studies | 8 | 2021 | 1574 | 0.340 |
Why?
|
| Efficiency | 1 | 2010 | 14 | 0.340 |
Why?
|
| Heart Failure | 4 | 2019 | 298 | 0.340 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2020 | 40 | 0.330 |
Why?
|
| Age Factors | 5 | 2018 | 1139 | 0.330 |
Why?
|
| Heart Transplantation | 3 | 2019 | 47 | 0.320 |
Why?
|
| Self Care | 1 | 2010 | 173 | 0.300 |
Why?
|
| Ventricular Dysfunction | 2 | 2020 | 4 | 0.290 |
Why?
|
| Thrombosis | 3 | 2015 | 81 | 0.290 |
Why?
|
| Follow-Up Studies | 8 | 2023 | 1051 | 0.280 |
Why?
|
| Pediatrics | 4 | 2014 | 69 | 0.280 |
Why?
|
| Palliative Care | 5 | 2023 | 61 | 0.280 |
Why?
|
| Heart | 3 | 2017 | 181 | 0.270 |
Why?
|
| Ankle Injuries | 1 | 2007 | 3 | 0.270 |
Why?
|
| Fibula | 1 | 2007 | 2 | 0.270 |
Why?
|
| Fracture Healing | 1 | 2007 | 4 | 0.270 |
Why?
|
| Weight-Bearing | 1 | 2007 | 31 | 0.270 |
Why?
|
| Opioid-Related Disorders | 1 | 2010 | 188 | 0.270 |
Why?
|
| Comorbidity | 4 | 2018 | 725 | 0.270 |
Why?
|
| Data Mining | 2 | 2017 | 30 | 0.260 |
Why?
|
| Health Status | 1 | 2010 | 432 | 0.260 |
Why?
|
| Risk Assessment | 7 | 2025 | 845 | 0.250 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 250 | 0.230 |
Why?
|
| Reoperation | 1 | 2025 | 31 | 0.230 |
Why?
|
| Medical Informatics | 2 | 2023 | 24 | 0.230 |
Why?
|
| Self Disclosure | 1 | 2005 | 43 | 0.230 |
Why?
|
| Ventricular Septum | 1 | 2024 | 2 | 0.220 |
Why?
|
| Adult | 12 | 2021 | 13458 | 0.220 |
Why?
|
| Benchmarking | 2 | 2017 | 33 | 0.220 |
Why?
|
| Complementary Therapies | 1 | 2005 | 51 | 0.220 |
Why?
|
| Young Adult | 6 | 2017 | 4936 | 0.220 |
Why?
|
| Heart-Assist Devices | 2 | 2019 | 37 | 0.210 |
Why?
|
| Coronary Disease | 1 | 2005 | 123 | 0.210 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2023 | 3 | 0.210 |
Why?
|
| Cohort Studies | 4 | 2019 | 1729 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 638 | 0.210 |
Why?
|
| Calcium-Binding Proteins | 2 | 2003 | 80 | 0.210 |
Why?
|
| Aged | 7 | 2018 | 7982 | 0.200 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2014 | 51 | 0.200 |
Why?
|
| Troponin I | 1 | 2003 | 18 | 0.200 |
Why?
|
| Methylprednisolone | 4 | 2011 | 17 | 0.200 |
Why?
|
| Communication | 1 | 2005 | 207 | 0.200 |
Why?
|
| Ventricular Function, Right | 2 | 2023 | 33 | 0.190 |
Why?
|
| Oxygen Consumption | 3 | 2016 | 111 | 0.190 |
Why?
|
| Sex Factors | 2 | 2018 | 1008 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 3 | 2013 | 176 | 0.190 |
Why?
|
| Coronary Care Units | 3 | 2016 | 3 | 0.190 |
Why?
|
| United States | 11 | 2025 | 5072 | 0.190 |
Why?
|
| Algorithms | 1 | 2025 | 508 | 0.180 |
Why?
|
| Cardiology | 3 | 2005 | 19 | 0.180 |
Why?
|
| Carbon Dioxide | 2 | 2016 | 86 | 0.170 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 173 | 0.170 |
Why?
|
| Middle Aged | 9 | 2018 | 11819 | 0.170 |
Why?
|
| Program Evaluation | 2 | 2013 | 358 | 0.170 |
Why?
|
| Smoking | 1 | 2007 | 1019 | 0.160 |
Why?
|
| Transposition of Great Vessels | 1 | 2020 | 3 | 0.160 |
Why?
|
| Preoperative Care | 6 | 2006 | 31 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2020 | 362 | 0.160 |
Why?
|
| Intraoperative Care | 3 | 2011 | 13 | 0.150 |
Why?
|
| Morbidity | 2 | 2019 | 97 | 0.150 |
Why?
|
| Logistic Models | 5 | 2019 | 1001 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 62 | 0.150 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 25 | 0.150 |
Why?
|
| Inflammation Mediators | 2 | 2015 | 138 | 0.150 |
Why?
|
| Homeostasis | 1 | 2020 | 193 | 0.150 |
Why?
|
| Colloids | 1 | 2018 | 15 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 20 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 3 | 2005 | 78 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2018 | 15 | 0.150 |
Why?
|
| Heart Arrest | 1 | 2019 | 52 | 0.150 |
Why?
|
| Vasodilator Agents | 2 | 2013 | 55 | 0.150 |
Why?
|
| Albumins | 1 | 2018 | 32 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2018 | 26 | 0.150 |
Why?
|
| Graft Rejection | 1 | 2018 | 43 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 33 | 0.140 |
Why?
|
| Canada | 2 | 2016 | 157 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2012 | 121 | 0.140 |
Why?
|
| Odds Ratio | 3 | 2015 | 587 | 0.140 |
Why?
|
| Heart Bypass, Right | 1 | 2018 | 1 | 0.140 |
Why?
|
| Health Care Rationing | 1 | 2017 | 5 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 94 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 42 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2017 | 10 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 50 | 0.140 |
Why?
|
| Causality | 2 | 2023 | 45 | 0.140 |
Why?
|
| Energy Intake | 1 | 2018 | 162 | 0.130 |
Why?
|
| Prenatal Care | 1 | 2018 | 82 | 0.130 |
Why?
|
| Recovery of Function | 2 | 2016 | 107 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2016 | 336 | 0.130 |
Why?
|
| Linear Models | 2 | 2015 | 311 | 0.130 |
Why?
|
| Endocrine System Diseases | 1 | 2016 | 16 | 0.130 |
Why?
|
| North America | 2 | 2013 | 85 | 0.130 |
Why?
|
| Ebstein Anomaly | 1 | 2016 | 1 | 0.130 |
Why?
|
| Anesthesia | 1 | 2016 | 16 | 0.120 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2016 | 12 | 0.120 |
Why?
|
| Basal Metabolism | 1 | 2016 | 6 | 0.120 |
Why?
|
| Tricuspid Valve | 1 | 2016 | 12 | 0.120 |
Why?
|
| Patient Selection | 1 | 2017 | 192 | 0.120 |
Why?
|
| Echocardiography, Doppler | 1 | 2016 | 41 | 0.120 |
Why?
|
| California | 1 | 2018 | 531 | 0.120 |
Why?
|
| Survival Rate | 2 | 2021 | 353 | 0.120 |
Why?
|
| Pulmonary Artery | 3 | 2023 | 33 | 0.120 |
Why?
|
| Endothelin-1 | 3 | 2005 | 57 | 0.110 |
Why?
|
| Hospitals, Pediatric | 2 | 2011 | 21 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2015 | 165 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2014 | 36 | 0.110 |
Why?
|
| Ischemic Preconditioning | 1 | 2014 | 49 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2015 | 190 | 0.110 |
Why?
|
| Calpain | 2 | 2005 | 35 | 0.110 |
Why?
|
| Hemodynamics | 5 | 2016 | 101 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 279 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 358 | 0.100 |
Why?
|
| Brain Ischemia | 2 | 2006 | 196 | 0.100 |
Why?
|
| Euthanasia, Passive | 1 | 2013 | 3 | 0.100 |
Why?
|
| Pressure Ulcer | 1 | 2013 | 6 | 0.100 |
Why?
|
| Triiodothyronine | 1 | 2013 | 36 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1221 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 2013 | 30 | 0.100 |
Why?
|
| Infection Control | 1 | 2013 | 17 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 42 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 22 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 39 | 0.100 |
Why?
|
| Incidence | 3 | 2025 | 1054 | 0.100 |
Why?
|
| Swine | 5 | 2005 | 205 | 0.100 |
Why?
|
| Enoxaparin | 1 | 2012 | 2 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 136 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2006 | 577 | 0.090 |
Why?
|
| Interferon-alpha | 2 | 2002 | 43 | 0.090 |
Why?
|
| Data Collection | 3 | 2016 | 210 | 0.090 |
Why?
|
| Blood Pressure | 1 | 2016 | 662 | 0.090 |
Why?
|
| Ontario | 3 | 2020 | 37 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 573 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 512 | 0.090 |
Why?
|
| Blood Preservation | 1 | 2011 | 6 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 2 | 2002 | 44 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3077 | 0.090 |
Why?
|
| Warfarin | 1 | 2012 | 66 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2011 | 574 | 0.090 |
Why?
|
| Anecdotes as Topic | 1 | 2010 | 6 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 467 | 0.090 |
Why?
|
| Pennsylvania | 1 | 2010 | 43 | 0.090 |
Why?
|
| Employer Health Costs | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cost Control | 1 | 2010 | 9 | 0.090 |
Why?
|
| Occupational Health | 1 | 2010 | 30 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 35 | 0.080 |
Why?
|
| Task Performance and Analysis | 1 | 2010 | 47 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 61 | 0.080 |
Why?
|
| Health Services | 1 | 2010 | 62 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2002 | 189 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1020 | 0.080 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2010 | 1 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 19 | 0.080 |
Why?
|
| Cause of Death | 1 | 2011 | 183 | 0.080 |
Why?
|
| Speech Recognition Software | 1 | 2009 | 1 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 825 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 40 | 0.080 |
Why?
|
| Telephone | 1 | 2009 | 35 | 0.080 |
Why?
|
| Managed Care Programs | 1 | 2009 | 39 | 0.080 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 47 | 0.080 |
Why?
|
| Stroke | 1 | 2013 | 348 | 0.070 |
Why?
|
| Internet | 1 | 2010 | 234 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 90 | 0.070 |
Why?
|
| Peroxidase | 2 | 2005 | 57 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 1112 | 0.070 |
Why?
|
| Pregnancy | 3 | 2020 | 1737 | 0.070 |
Why?
|
| Animals | 7 | 2016 | 16695 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2010 | 541 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2007 | 23 | 0.070 |
Why?
|
| Rotation | 1 | 2007 | 27 | 0.070 |
Why?
|
| Radiography | 1 | 2007 | 72 | 0.070 |
Why?
|
| Heart Arrest, Induced | 2 | 2004 | 4 | 0.070 |
Why?
|
| Pulmonary Circulation | 2 | 2004 | 4 | 0.070 |
Why?
|
| Gestational Age | 2 | 2018 | 195 | 0.060 |
Why?
|
| Infant Mortality | 2 | 2020 | 64 | 0.060 |
Why?
|
| Uracil | 1 | 2005 | 9 | 0.060 |
Why?
|
| Ventricular Function, Left | 2 | 2004 | 111 | 0.060 |
Why?
|
| American Hospital Association | 1 | 2005 | 3 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 21 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 39 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 32 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2005 | 74 | 0.060 |
Why?
|
| Tidal Volume | 1 | 2005 | 9 | 0.060 |
Why?
|
| Attitude to Health | 2 | 2005 | 336 | 0.060 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2005 | 35 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2005 | 57 | 0.060 |
Why?
|
| ROC Curve | 1 | 2025 | 157 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2005 | 224 | 0.050 |
Why?
|
| Prognosis | 2 | 2018 | 850 | 0.050 |
Why?
|
| Hawaii | 1 | 2010 | 2004 | 0.050 |
Why?
|
| Education, Medical | 1 | 2005 | 117 | 0.050 |
Why?
|
| Nitrogen | 1 | 2005 | 83 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2005 | 164 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2003 | 29 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2003 | 27 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2014 | 305 | 0.050 |
Why?
|
| Premedication | 1 | 2002 | 4 | 0.050 |
Why?
|
| Social Class | 1 | 2005 | 286 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2023 | 122 | 0.050 |
Why?
|
| Ribavirin | 1 | 2002 | 20 | 0.050 |
Why?
|
| Calcineurin | 1 | 2002 | 22 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 107 | 0.050 |
Why?
|
| Behavioral Medicine | 1 | 2002 | 11 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2002 | 46 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2003 | 1617 | 0.050 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2002 | 37 | 0.040 |
Why?
|
| Macrophages | 1 | 2005 | 515 | 0.040 |
Why?
|
| Affective Symptoms | 1 | 2002 | 60 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2023 | 120 | 0.040 |
Why?
|
| Hospitalization | 1 | 2005 | 482 | 0.040 |
Why?
|
| Myocardium | 1 | 2002 | 251 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2016 | 184 | 0.040 |
Why?
|
| Perinatal Care | 1 | 2020 | 14 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 33 | 0.040 |
Why?
|
| Depression | 3 | 2002 | 837 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 23 | 0.040 |
Why?
|
| Prevalence | 3 | 2011 | 1597 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 487 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2018 | 5 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2002 | 381 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2002 | 362 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 53 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2018 | 20 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 53 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2017 | 487 | 0.040 |
Why?
|
| Anemia | 1 | 2018 | 52 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2018 | 112 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 146 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2017 | 39 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 708 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 10 | 0.030 |
Why?
|
| Perinatal Mortality | 1 | 2016 | 4 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 16 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 602 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2015 | 3 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2015 | 23 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 156 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 796 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 733 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 61 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 54 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 2 | 2006 | 72 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 47 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 78 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 52 | 0.030 |
Why?
|
| New York | 1 | 2015 | 88 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2016 | 99 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 438 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1541 | 0.030 |
Why?
|
| Hypothermia, Induced | 2 | 2005 | 27 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1058 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 249 | 0.030 |
Why?
|
| Hyperthyroidism | 1 | 2013 | 8 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 2013 | 35 | 0.030 |
Why?
|
| Administration, Inhalation | 2 | 2005 | 92 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 2005 | 350 | 0.020 |
Why?
|
| Ventricular Function | 1 | 2012 | 8 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1266 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 2011 | 11 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 37 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 35 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 289 | 0.020 |
Why?
|
| Public Health Informatics | 1 | 2010 | 9 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2009 | 5 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2009 | 90 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2009 | 230 | 0.020 |
Why?
|
| Quality of Life | 2 | 2002 | 599 | 0.020 |
Why?
|
| Pain | 1 | 1990 | 283 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 14 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2005 | 10 | 0.020 |
Why?
|
| Thymine | 1 | 2005 | 25 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2005 | 92 | 0.010 |
Why?
|
| Chlorides | 1 | 2005 | 59 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 82 | 0.010 |
Why?
|
| Heme | 1 | 2005 | 72 | 0.010 |
Why?
|
| Lung Compliance | 1 | 2005 | 3 | 0.010 |
Why?
|
| Health Behavior | 1 | 2009 | 568 | 0.010 |
Why?
|
| Aorta | 1 | 2005 | 197 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 385 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 205 | 0.010 |
Why?
|
| Temperature | 1 | 2005 | 314 | 0.010 |
Why?
|
| Neutrophil Activation | 1 | 2004 | 9 | 0.010 |
Why?
|
| Heart Septum | 1 | 2004 | 6 | 0.010 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2004 | 8 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 84 | 0.010 |
Why?
|
| Random Allocation | 1 | 2004 | 145 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 458 | 0.010 |
Why?
|
| Monocytes | 1 | 2005 | 275 | 0.010 |
Why?
|
| Interleukins | 1 | 2003 | 37 | 0.010 |
Why?
|
| Body Temperature | 1 | 2003 | 35 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 774 | 0.010 |
Why?
|
| Nicotine | 1 | 2005 | 290 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 594 | 0.010 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 2002 | 6 | 0.010 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2002 | 7 | 0.010 |
Why?
|
| Myofibrils | 1 | 2002 | 12 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 959 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 153 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2002 | 11 | 0.010 |
Why?
|
| Perfusion | 1 | 2002 | 39 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 439 | 0.010 |
Why?
|
| Connexin 43 | 1 | 2002 | 41 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 233 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 181 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 711 | 0.010 |
Why?
|
| Health Services Research | 1 | 2002 | 161 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 355 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 522 | 0.010 |
Why?
|
| Lung | 1 | 2004 | 484 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 1169 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2002 | 126 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 661 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 658 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1265 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 729 | 0.010 |
Why?
|
| Hypertension | 1 | 2002 | 823 | 0.010 |
Why?
|
| Mice | 1 | 2002 | 6490 | 0.010 |
Why?
|
| MMPI | 1 | 1990 | 11 | 0.010 |
Why?
|
| Frustration | 1 | 1990 | 7 | 0.010 |
Why?
|
| Anger | 1 | 1990 | 27 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1990 | 181 | 0.000 |
Why?
|
| Fear | 1 | 1990 | 271 | 0.000 |
Why?
|
| Anxiety | 1 | 1990 | 847 | 0.000 |
Why?
|